期刊
CHEMMEDCHEM
卷 11, 期 12, 页码 1270-1283出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201500418
关键词
Alzheimer's disease; butyrylcholinesterase; cannabinoid receptor ligands; molecular dynamics; multitarget compounds
资金
- German Science Foundation (Deutsche Forschungsgemeinschaft) [DFG DE1546/6-1, DE1546/4-1]
- Elite Network of Bavaria
A pharmacophore model for butyrylcholinesterase (BChE) inhibitors was applied to a human cannabinoid subtype 2 receptor (hCB(2)R) agonist and verified it as a first-generation lead for respective dual-acting compounds. The design, synthesis, and pharmacological evaluation of various derivatives led to the identification of aminobenzimidazoles as second-generation leads with micro-or sub-micromolar activities at both targets and excellent selectivity over hCB(1) and AChE, respectively. Computational studies of the first-and second-generation lead structures by applying molecular dynamics (MD) on the active hCB(2)R model, along with docking and MD on hBChE, has enabled an explanation of their binding profiles at the protein levels and opened the way for further optimization. Dualacting compounds with balanced affinities and excellent selectivities could be obtained that represent leads for treatment of both cognitive and pathophysiological impairment occurring in neurodegenerative disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据